Form Type and Filing Date: Current Report on Form 8-K filed by Abbott Laboratories on January 22, 2026, reporting events as of that same date Item 2.02 - Results of Operations and Financial Condition: The filing indicates disclosure of results of operations and financial condition information (specific financial details not fully visible in the header section provided) Item 9.01 - Financial…

Our analysis rates this filing NEUTRAL. Abbott presents a balanced risk profile appropriate for a stable, large-cap healthcare company. While the Exact Sciences acquisition introduces meaningful execution risk (severity 5) and COVID-19 testing decline represents a structural headwind, these are…

Concern level: ELEVATED (4.8/10). Key factors: Exact Sciences acquisition (severity 5) introduces material integration risk and regulatory approval uncertainty for Q2 2026 close; COVID-19 testing revenue explicitly noted as 'significantly declined' - structural headwind to diagnostics segment requiring organic growth offset; 2026 EPS guidance growth rate (10% at midpoint) appears flat to 2025…

Notable risk changes: Exact Sciences acquisition announced with Q2 2026 expected close - introduces regulatory approval risk and integration execution risk for large cancer diagnostics platform; COVID-19 testing revenue explicitly disclosed as significantly declined, requiring organic growth from core business to offset this headwind; 2026 EPS guidance of $5.55-$5.80 (10% growth at midpoint) is lower growth rate…

The model predicts ABT will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.